LMN-201

Lumen Bioscience, Inc. · Phase 2 active Small molecule

At a glance

Generic name	LMN-201
Sponsor	Lumen Bioscience, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

LMN-201 for Prevention of C. Difficile Infection Recurrence (PHASE2, PHASE3)
Exploratory Study to Assess Delivery of LMN-201 Components Via Enteric Capsules in the Gut of Individuals With Ostomies (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LMN-201 CI brief — competitive landscape report
LMN-201 updates RSS · CI watch RSS
Lumen Bioscience, Inc. portfolio CI